Kidney Cancer

A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.

A variety of novel treatments, including immunotherapies, extend life for patients with advanced kidney cancer.

Getting kidney cancer treatment during the COVID-19 pandemic.

Kidney cancer positives that might come from this pandemic.

How kidney cancer affects the risks of coronavirus.

A message from the KCA’s CEO and President about COVID-19.

Kidney cancer changed how Tracie saw her world.

On his motorcycle, Stewy rides for kidney cancer.

A clinical trial and a positive attitude helped Bill Brown ring the bell.

Dawne Gee worked hard to get answers about her kidney cancer.

“These results continue to support pembrolizumab (Keytruda) plus axitinib (Inlyta) as a standard of care for patients with previously untreated advanced RCC,” said lead study author Dr. Elizabeth R. Plimack.

The HIF-2a Inhibitor induced clinical responses among patients with von Hippel-Lindau disease–associated kidney cancer, according to results presented at the 2020 ASCO Virtual Scientific Program.

When compared with Nexavar, Fotivda showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.

“Those who are doing well and are stable in terms of safety and tolerability can come into the office less often,” Dr. David R. Spigel, said. “(This is) a big win.”

Dr. Brian Rini discussed the benefits of treating patients with relapsed or refractory renal cell carcinoma with the vascular endothelial growth factor tyrosine kinase inhibitor.

Further follow up of the CheckMate-214 trial continues to show the superior long-term outcomes of Opdivo and Yervoy in treatment of patients with advanced renal cell carcinoma.

Patients with advanced renal cell carcinoma may soon have a new option in the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib).

“I’m not going to give up on that just because of this pandemic. Health is most important, as it should be for us cancer survivors.”

Keytruda, an immunotherapy that treats a variety of adult cancers, can now be given at a higher dose that requires fewer visits to clinics for infusions to support social distancing during the COVID-19 pandemic.

“I thought, you know what I have control right now: if I'm going to laugh, if I'm going to enjoy my family, or if I'm going to hide in a corner and cry all day. I'm not going to do that. I'm not going to let cancer do that to me.”

Once a patient progresses following initial treatment for kidney cancer, one expert says TKIs are the next step in therapy.

Different combinations of immunotherapy with chemotherapy are helping patients with renal cell carcinoma live longer.

The first study to look at cancer prevalence in transgender people and examine the health of transgender cancer survivors also found concerning health trends among transgender women and gender nonconforming people.

Young Investigator and Advanced Discovery Awards will advance kidney cancer research, as the Kidney Cancer Association opens up its grant applications.

African American race was associated with longer survival in non-clear cell metastatic renal cell carcinoma compared with Hispanic and Caucasian patients.

From New Jersey Governor Phil Murphy announcing he will undergo surgery to remove a potentially cancerous tumor on his kidney to an NHL team granting a 15-year-old fan with cancer the ultimate wish, here’s what is making headlines in the cancer space this week.

Utilizing the data of the CheckMate 9ER trial, researchers believe that combination therapies in the treatment of patients with renal cell carcinoma are the future of the landscape.

Here’s a look at what’s inside our 2020 Winter issue.

Treatments for renal cell carcinoma are showing effectiveness in the short term, but with the help of new trials, researchers are looking to expand their impact for long term treatment.

The landscape for patients with renal cell carcinoma could potentially change as the use of immune checkpoint inhibition shows promise for these patients.